These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 22739529)
21. [Levodopa medications in the treatment of Parkinson's disease]. Fedorova NV; Iablonskaia AIu; Bel'gusheva ME Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(5):30-6. PubMed ID: 21666590 [TBL] [Abstract][Full Text] [Related]
22. [Long term experience with Stalevo in Szeged, Hungary]. Klivényi P; Vécsei L Ideggyogy Sz; 2009 May; 62(5-6):178-80. PubMed ID: 19579666 [TBL] [Abstract][Full Text] [Related]
23. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life]. Klivényi P; Vécsei L Ideggyogy Sz; 2008 Jan; 61(1-2):42-8. PubMed ID: 18372774 [TBL] [Abstract][Full Text] [Related]
25. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589 [TBL] [Abstract][Full Text] [Related]
26. Improving quality of life in early Parkinson's. Health News; 2005 Feb; 11(2):2. PubMed ID: 15732144 [No Abstract] [Full Text] [Related]
27. Sinemet CR in Parkinson's disease. Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878 [TBL] [Abstract][Full Text] [Related]
28. [Livedo reticularis secondary to amantadine in a patient with Parkinson disease]. Salvado M; Hernández-Vara J Med Clin (Barc); 2014 Feb; 142(4):186. PubMed ID: 24012443 [No Abstract] [Full Text] [Related]
29. [Drug therapy of Parkinson's disease]. Zhou XD Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905 [No Abstract] [Full Text] [Related]
30. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination]. Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947 [TBL] [Abstract][Full Text] [Related]
31. [COMT inhibitors]. Bornkessel B Med Monatsschr Pharm; 1999 May; 22(5):138-41. PubMed ID: 10365553 [No Abstract] [Full Text] [Related]
32. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease. Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701 [TBL] [Abstract][Full Text] [Related]
33. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. Simonson W; Hauser RA; Schapira AH Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397 [TBL] [Abstract][Full Text] [Related]
34. Levodopa-associated hemifacial dystonia. Mark MH; Sage JI Mov Disord; 1991; 6(4):383. PubMed ID: 1758464 [No Abstract] [Full Text] [Related]
35. Medical treatment of Parkinson's disease. Ahlskog JE Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977 [No Abstract] [Full Text] [Related]
36. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
37. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies. Worth PF Pract Neurol; 2013 Jun; 13(3):140-52. PubMed ID: 23487815 [TBL] [Abstract][Full Text] [Related]
38. [Treatment in Parkinson disease]. Takáts A Orv Hetil; 2004 Apr; 145(15):833-4. PubMed ID: 15188639 [No Abstract] [Full Text] [Related]